Shares of United Therapeutics Co. (NASDAQ:UTHR) have received a consensus rating of “Hold” from the fifteen ratings firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $120.36.
A number of equities research analysts have issued reports on the company. UBS Group raised United Therapeutics from a “sell” rating to a “neutral” rating and decreased their target price for the stock from $115.00 to $94.00 in a research report on Friday, May 17th. They noted that the move was a valuation call. Wedbush reiterated a “buy” rating and set a $273.00 price objective on shares of United Therapeutics in a research note on Thursday, August 1st. ValuEngine upgraded United Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research cut United Therapeutics from a “buy” rating to a “hold” rating and set a $86.00 target price on the stock. in a report on Wednesday, August 14th. Finally, LADENBURG THALM/SH SH upgraded United Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $103.00 to $106.00 in a report on Thursday, August 1st.
In related news, Director Richard Giltner sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $79.05, for a total transaction of $395,250.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $395,250. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Raymond Dwek sold 3,750 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $76.11, for a total value of $285,412.50. Following the completion of the sale, the director now directly owns 3,750 shares of the company’s stock, valued at $285,412.50. The disclosure for this sale can be found here. 8.80% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Nissay Asset Management Corp Japan ADV raised its position in shares of United Therapeutics by 2.9% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,029 shares of the biotechnology company’s stock worth $590,000 after buying an additional 144 shares in the last quarter. NEXT Financial Group Inc grew its stake in shares of United Therapeutics by 72.7% in the second quarter. NEXT Financial Group Inc now owns 475 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 200 shares during the last quarter. Gabelli Funds LLC bought a new stake in shares of United Therapeutics in the second quarter worth about $390,000. Swiss National Bank boosted its position in United Therapeutics by 2.6% during the 1st quarter. Swiss National Bank now owns 145,200 shares of the biotechnology company’s stock valued at $17,042,000 after acquiring an additional 3,700 shares in the last quarter. Finally, AGF Investments LLC boosted its position in United Therapeutics by 7.9% during the 2nd quarter. AGF Investments LLC now owns 20,383 shares of the biotechnology company’s stock valued at $1,591,000 after acquiring an additional 1,499 shares in the last quarter. 94.16% of the stock is owned by institutional investors.
NASDAQ UTHR traded down $2.41 on Thursday, hitting $80.51. 27,479 shares of the company were exchanged, compared to its average volume of 541,395. The company’s 50 day moving average price is $80.73 and its 200-day moving average price is $93.03. The company has a debt-to-equity ratio of 0.31, a current ratio of 4.62 and a quick ratio of 4.41. The firm has a market capitalization of $3.64 billion, a P/E ratio of 6.01 and a beta of 0.92. United Therapeutics has a twelve month low of $74.31 and a twelve month high of $129.59.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $4.66 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.40 by $2.26. The company had revenue of $373.60 million for the quarter, compared to analysts’ expectations of $331.78 million. United Therapeutics had a negative return on equity of 4.54% and a negative net margin of 7.69%. As a group, equities analysts expect that United Therapeutics will post -1.96 EPS for the current year.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Article: What is the Fibonacci sequence?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.